Andrew J Bryant,
ASO PROF
Department:
MD-PULMONARY MEDICINE
Business Phone:
(352) 273-8737
Business Email:
andrew.bryant@medicine.ufl.edu
About Andrew J Bryant
As an associate professor of medicine at the University of Florida Division of Pulmonary, Critical Care and Sleep Medicine, I treat patients with pulmonary hypertension. Likewise, my primary research is focused in pulmonary hypertension. My overall objective is to define the systematic effects of pulmonary hypertension, specifically the role of bone marrow-derived cells in disease progression, and using data to uncover new drug targets for treatment of pulmonary hypertension. Additionally, I wear the hat of general pulmonologist and critical care physician. As a physician, I strive to provide excellent care tailored to my patients’ individual needs.
I earned my medical degree from Wake Forest University School of Medicine. Then, I went on to complete my residency in internal medicine and fellowship in pulmonary and critical care medicine at Vanderbilt University. I hold several professional affiliations, including the American College of Physicians, Society of Critical Care Medicine, American College of Chest Physicians and the American Thoracic Society.
I have been fortunate to receive multiple awards for excellence in research from the American Thoracic Society, American Lung Association and several other biomedical-related foundations. My current research projects are funded through two National Institutes of Health grants.
In my leisure time, I enjoy traveling, spending time with my family and learning how to play the classical guitar.
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-9433-3049
Publications
2024
Non–Interferon-Dependent Role of STING Signaling in Pulmonary Hypertension
Arteriosclerosis, Thrombosis, and Vascular Biology.
44(1):124-142
[DOI] 10.1161/atvbaha.123.320121.
2024
The common TMEM173 HAQ, AQ alleles rescue CD4 T cellpenia, restore T-regs, and prevent SAVI (N153S) inflammatory disease in mice.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2023.10.05.561109.
[PMID] 37886547.
2023
A review of cardio-pulmonary microvascular dysfunction in pulmonary hypertension.
American heart journal plus : cardiology research and practice.
26
[DOI] 10.1016/j.ahjo.2023.100255.
[PMID] 38510189.
2023
ACE2 overexpression in corticotropin-releasing-hormone cells offers protection against pulmonary hypertension.
Frontiers in neuroscience.
17
[DOI] 10.3389/fnins.2023.1223733.
[PMID] 37638323.
2023
Defining the age-dependent and tissue-specific circadian transcriptome in male mice.
Cell reports.
42(1)
[DOI] 10.1016/j.celrep.2022.111982.
[PMID] 36640301.
2022
A wrinkle in time: circadian biology in pulmonary vascular health and disease
American Journal of Physiology-Lung Cellular and Molecular Physiology.
322(1):L84-L101
[DOI] 10.1152/ajplung.00037.2021.
[PMID] 34850650.
2022
Apparent Absence of BMAL1-Dependent Skeletal Muscle–Kidney Cross Talk in Mice
Biomolecules.
12(2)
[DOI] 10.3390/biom12020261.
[PMID] 35204763.
2022
Cardiopulmonary disease as sequelae of long-term COVID-19: Current perspectives and challenges.
Frontiers in medicine.
9
[DOI] 10.3389/fmed.2022.1041236.
[PMID] 36530872.
2022
CHK yourself, before you wreck yourself: targeting the DNA damage response in secondary pulmonary hypertension.
Thorax.
77(3):218-219
[DOI] 10.1136/thoraxjnl-2021-217882.
[PMID] 34417351.
2022
Fecal matter transplant from Ace2 overexpressing mice counteracts chronic hypoxia-induced pulmonary hypertension.
Pulmonary circulation.
12(1)
[DOI] 10.1002/pul2.12015.
[PMID] 35506083.
2022
Liver regeneration and ethanol detoxification: A new link in YAP regulation of ALDH1A1 during alcohol-related hepatocyte damage.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
36(4)
[DOI] 10.1096/fj.202101686R.
[PMID] 35218575.
2021
Circadian Rhythm Effects on the Molecular Regulation of Physiological Systems.
Comprehensive Physiology.
12(1):2769-2798
[DOI] 10.1002/cphy.c210011.
[PMID] 34964116.
2021
Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling
British Journal of Pharmacology.
178(1):187-202
[DOI] 10.1111/bph.14945.
[PMID] 31793661.
2021
Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.
British journal of pharmacology.
178(1):172-186
[DOI] 10.1111/bph.15036.
[PMID] 32128790.
2021
Likelihood-based tests for detecting circadian rhythmicity and differential circadian patterns in transcriptomic applications.
Briefings in bioinformatics.
22(6)
[DOI] 10.1093/bib/bbab224.
[PMID] 34117739.
2021
The Third Man: DNA sensing as espionage in pulmonary vascular health and disease
Pulmonary Circulation.
11(1):1-16
[DOI] 10.1177/2045894021996574.
[PMID] 33738095.
2020
Hepatocyte nuclear factor 4α negatively regulates connective tissue growth factor during liver regeneration.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
34(4):4970-4983
[DOI] 10.1096/fj.201902382R.
[PMID] 32057145.
2019
A checkpoint on innate myeloid cells in pulmonary arterial hypertension
Pulmonary Circulation.
9(1):1-5
[DOI] 10.1177/2045894018823528.
[PMID] 30562157.
2019
Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia.
American journal of physiology. Lung cellular and molecular physiology.
317(4):L434-L444
[DOI] 10.1152/ajplung.00156.2019.
[PMID] 31364370.
2018
Involvement of Microglial Cells in Hypoxia-induced Pulmonary Hypertension.
American journal of respiratory cell and molecular biology.
59(2):271-273
[DOI] 10.1165/rcmb.2018-0042LE.
[PMID] 30067089.
2018
Myeloid-Derived Suppressor Cells and Pulmonary Hypertension.
International journal of molecular sciences.
19(8)
[DOI] 10.3390/ijms19082277.
[PMID] 30081463.
2018
Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension.
American journal of respiratory cell and molecular biology.
58(2):170-180
[DOI] 10.1165/rcmb.2017-0214OC.
[PMID] 28862882.
2018
rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling.
Frontiers in physiology.
9
[DOI] 10.3389/fphys.2018.00271.
[PMID] 29731719.
2018
Transforming growth factor beta1 targets estrogen receptor signaling in bronchial epithelial cells.
Respiratory research.
19(1)
[DOI] 10.1186/s12931-018-0861-5.
[PMID] 30165855.
2018
Vascular Endothelial Cell-Specific Connective Tissue Growth Factor (CTGF) Is Necessary for Development of Chronic Hypoxia-Induced Pulmonary Hypertension.
Frontiers in physiology.
9
[DOI] 10.3389/fphys.2018.00138.
[PMID] 29535639.
2016
“A small leak will sink a great ship”: hypoxia-inducible factor and group III pulmonary hypertension.
Receptors & clinical investigation.
3(1)
[PMID] 27446973.
2016
Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension.
American journal of physiology. Lung cellular and molecular physiology.
310(3):L249-62
[DOI] 10.1152/ajplung.00258.2015.
[PMID] 26637636.
2015
Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis.
Pulmonary circulation.
5(4):681-90
[DOI] 10.1086/683811.
[PMID] 26697175.
2013
Alcohol intolerance associated with Hodgkin lymphoma.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
185(8)
[DOI] 10.1503/cmaj.120974.
[PMID] 23091182.
2013
β-catenin in the alveolar epithelium protects from lung fibrosis after intratracheal bleomycin.
American journal of respiratory and critical care medicine.
187(6):630-9
[DOI] 10.1164/rccm.201205-0972OC.
[PMID] 23306543.
2012
Through a glass, darkly.
Archives of internal medicine.
172(13):985-6
[DOI] 10.1001/archinternmed.2012.2765.
[PMID] 22777628.
2006
Anesthetic preconditioning with sevoflurane does not protect the spinal cord after an ischemic-reperfusion injury in the rat.
Anesthesia and analgesia.
102(5):1341-7
[PMID] 16632806.
2006
The degree of atherosclerosis in the descending aorta does not predict poor in-hospital outcome after surgery requiring cardiopulmonary bypass.
Journal of cardiothoracic and vascular anesthesia.
20(2):149-55
[PMID] 16616652.
Grants
Dec 2023
ACTIVE
Tuning complement-mediated immunity in aspergillosis: a systems medicine approach
Role: Other
Funding: NATL INST OF HLTH NIAID
Apr 2023
ACTIVE
Neuroimmune axis contribution to the pathophysiology of pulmonary hypertension
Role: Other
Funding: NATL INST OF HLTH NHLBI
May 2022
– May 2023
2022 Student Scholarships in Cardiovascular Disease
Role: Other
Funding: AMER HEART ASSOCIATION
Aug 2020
– Aug 2023
Myeloid cell senescence in the development of pulmonary hypertension
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Apr 2020
ACTIVE
Role of ADAM17 in MDSC-Mediated Development of Pulmonary Hypertension
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Jan 2020
– Dec 2021
Involvement of Neuroinflammation in Pulmonary Hypertension
Role: Other
Funding: AMER HEART ASSOCIATION
Aug 2019
ACTIVE
Role of CXCR2-mediated cell trafficking in pulmonary vascular remodeling
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Jul 2018
– Jan 2020
Role of myeloid-derived suppressor cells in pulmonary hypertension associated with pulmonary fibrosis
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Jul 2018
– Jun 2021
Role of MDSCs in pulmonary hypertension associated with pulmonary fibrosis
Role: Principal Investigator
Funding: PARKER B FRANCIS FELLOWSHIP FOU
Jul 2017
– Dec 2019
Role of CXCR2-mediated cell trafficking in pulmonary hypertension
Role: Principal Investigator
Funding: AMER LUNG ASSO
Jun 2017
– Dec 2019
Role of myeloid-derived suppressor cell trafficking in development of pulmonary hypertension
Role: Principal Investigator
Funding: GILEAD SCIENCES
Apr 2017
– Mar 2018
Together: Transforming and Translating Discovery to Improve Health
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Jan 2017
– Dec 2018
Role of myeloid-derived suppressor cell trafficking in development of pulmonary hypertension
Role: Principal Investigator
Funding: UF FOUNDATION
via LANDENBERGER RES FOU, MARGARET Q.
Apr 2016
– Mar 2017
TOGETHER: TRANSFORMING AND TRANSLATING DISCOVERY TO IMPROVE ,HEALTH ,
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Jun 2001
– Dec 2022
01040902
Role: Project Manager
Funding: GRIFOLS SA
Contact Details
Phones:
- Business:
- (352) 273-8737
Emails:
- Business:
- andrew.bryant@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100225
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100225
GAINESVILLE FL 32610